Article
The effects of oxiracetam (ISF 2522) in patients with organic brain syndrome (a double‐blind controlled study with piracetam)
Abstract
Itil, T.M., G.N. Menon, M. Bozak, and A. Songar: The effects of oxiracetam, (ISF 2522) in patients with organic brain syndrome (a double‐blind controlled study with piracetam). Drug Dev. Res. 2:447–461, 1982.
In a double‐blind controlled trial, the clinical effects of oxiracetam, a new “nootropic” compound, were investigated in a group of 60 elderly patients with organic mental disorders (DSM‐III). The starting dose of both oxiracetam and the control drug, piracetam, was 400 mg. The dosage was increased by 400 mg at weekly intervals up to 2,400 mg daily (sixth week). During the following 6 weeks the administered dose was fixed at 2,400 mg daily. Most of the important target symptoms improved significantly over time, both subjectively (i.e., rating scales) and objectively (i.e., psychological tests), after administration of either oxiracetam or piracetam. In comparison to piracetam, oxiracetam exhibited more statistically significant improvement in the memory factor, whereas piracetam showed more improvement than oxiracetam in factors of paranoid ideation and agitation. Both drugs were tolerable and did not elicit any significant side effects. It was postulated that “nootropics” may represent a new group of CNS effective compounds, and thus be a “second generation” of psychotropics, which have more direct effects on the central target organs than are presently found in the “classical” psychotropics.
Citing Literature
Number of times cited: 28
- Jair C. Soares and Samuel Gershon, Advances in the pharmacotherapy of Alzheimer's disease, European Archives of Psychiatry and Clinical Neuroscience, 244, 5, (261), (1994).
- S. V. Krapivin, T. A. Voronina, N. N. Bogdanov and L. D. Smirnov, Neurophysiological analysis of the effects of nooglutil as opposed to known nootropic drugs, Pharmaceutical Chemistry Journal, 28, 4, (220), (1994).
- A. Borromei, R. Caramelli, M. Cerisoli, R. Gaggi, A.M. Gianni, A. Lozito, B. Vargiu and C. Alvisi, Effects of oxiracetam on organic brain syndrome following activation of the high-affinity choline uptake system: A neurochemical analysis of the cerebrospinal fluid of four patients, Current Therapeutic Research, 54, 2, (194), (1993).
- Maria Grazia Giovannini, Paola Rodinò, Donatella Mutolo and Gincarlo Pepeu, Oxiracetam and aniracetam increase acetylcholine release from the rat hippocampus in vivo, Drug Development Research, 28, 4, (503-509), (2004).
- Stephen R. Dager, J. Pierre Loebel, Keith Claypool, Mary Case, Christopher B. Budech and David L. Dunner, Oxiracetam in the treatment of primary dementia of the Alzheimer's type: A small case series, International Journal of Geriatric Psychiatry, 7, 12, (905-912), (2004).
- David D. P. Laffan, Markus Bänziger, Lauren Duc, Andrew R. Evans, John F. McGarrity and Thomas Meul, An Efficient Synthesis of Racemic 4‐Hydroxy‐2‐oxo‐1‐pyrrolidineacetamide (Oxiracetam) Using Tetramic‐Acid Intermediates, Helvetica Chimica Acta, 75, 3, (892-900), (2004).
- H. P. Gschwind, H. Schütz, N. Wigger and P. Bentley, Absorption and disposition of14C-labelled oxiracetam in rat, dog and man, European Journal of Drug Metabolism and Pharmacokinetics, 17, 1, (67), (1992).
- Susan W. Miller, Janelle M. Mahoney and Michael W. Jann, Therapeutic Frontiers in Alzheimer's Disease, Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 12, 3, (217-231), (2012).
- Corrado Lacomba, Raffaele Cagiano, Oronzo Maci, Jaqueline Valerio and Vincenzo Cuomo, Effects of L‐alpha‐glycerylphosphorylcholine on the EEG power spectrum in the rat, Drug Development Research, 26, 1, (101-107), (2004).
- S. Consolo, P. Salmoiraghi, D. Amoroso and K. Kolasa, Treatment with Oxiracetam or Choline Restores Cholinergic Biochemical and Pharmacological Activities in Striata of Decorticated Rats, Journal of Neurochemistry, 54, 2, (571-577), (2006).
- J. B. Lecaillon, J. P. Dubois, H. Coppens, T. Darragon, G. Reumond, N. Pozet, J. Traeger and G. Lambrey, Pharmacokinetics of oxiracetam in patients with renal impairment after a 800 mg single oral dose, European Journal of Drug Metabolism and Pharmacokinetics, 15, 3, (231), (1990).
- J. B. Lecaillon, J. P. Dubois, H. Coppens, T. Darragon, W. Theobald, G. Reumond and H. Beck, Pharmacokinetics of oxiracetam in elderly patients after 800 mg oral doses, comparison with non-geriatric healthy subjects, European Journal of Drug Metabolism and Pharmacokinetics, 15, 3, (223), (1990).
- Barry Baumel, Larry Eisner, Michael Karukin, Rosemary Macnamara, Richard J. Katz and Joseph Deveaugh-Geiss, Oxiracetam in the treatment of multi-infarct dementia, Progress in Neuro-Psychopharmacology and Biological Psychiatry, 13, 5, (673), (1989).
- Mario Sansone and Alberto Oliverio, Avoidance facilitation by nootropics, Progress in Neuro-Psychopharmacology and Biological Psychiatry, 13, (S89), (1989).
- Guido Gainottin, Ugo Nocentini and Elio Sena, Can the pattern of neuropsychological improvement obtained with cholinergic drugs be used to infer a cholinergic mechanism in other nootropic drugs?, Progress in Neuro-Psychopharmacology and Biological Psychiatry, 13, (S47), (1989).
- Helen H. Ong and Richard C. Allen, Chapter 33. To Market, To Market – 1987, , 10.1016/S0065-7743(08)60861-1, (325-348), (1988).
- Cheryl Waters, Cognitive Enhancing Agents: Current Status in the Treatment of Alzheimer's Disease, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques, 15, 03, (249), (1988).
- A. Mangoni, C. Perin, S. Smirne, I. Piccolo, F. De Filippi, C. Marchetti, A. Motta and G. C. Monza, A double‐blind, placebo‐controlled study with oxiracetam in demented patients administered the Luria‐Nebraska Neuropsychological Battery, Drug Development Research, 14, 3‐4, (217-222), (2004).
- Maurice W. Dysken, Susan Anton‐Johnson, Linda Klein, Michael Kuskowski, Lawrence J. Schut, Steven H. Miles, Gabe J. Maletta and Richard De Jong, CI‐911: A placebo‐controlled study in patients with primary degenerative dementia, Drug Development Research, 12, 3‐4, (267-270), (2004).
- A. Hjorther, E. Browne, K. Jakobsen, P. Viskum and F. Gyntelberg, Organic brain syndrome treated with oxiracetam; A double‐blind randomized controlled trial, Acta Neurologica Scandinavica, 75, 4, (271-276), (2009).
- Lina Ney, Offene vergleichsstudie mit nootropil® in der anästhesie, European Surgery, 18, 5-6, (509), (1986).
- Thomas Crook, Geriatric psychopathology: An overview of the ailments and current therapies, Drug Development Research, 5, 1, (5-23), (2004).
- THOMAS CROOK, Clinical Drug Trials in Alzheimer's Disease, Annals of the New York Academy of Sciences, 444, 1, (428-436), (2006).
- Fred M. Hershenson and John G. Marriott, Chapter 4. Cognitive Disorders, , 10.1016/S0065-7743(08)60680-6, (31-40), (1984).
- E.A. Babayan, A.V. Astahova, V.K. Lepakhin and A.S. Lopatin, Central nervous system stimulants and anorectic agents, , 10.1016/S0378-6080(84)80005-7, (1-21), (1984).
- Virginia J. Galizia, Pharmacotherapy of Memory Loss in the Geriatric Patient, Drug Intelligence & Clinical Pharmacy, 18, 10, (784), (1984).
- E. Perucca, A. Albrici, G. Gatti, R. Spalluto, M. Visconti and A. Crema, Pharmacokinetics of oxiracetam following intravenous and oral administration in healthy volunteers, European Journal of Drug Metabolism and Pharmacokinetics, 9, 3, (267), (1984).
- G. Chouinard, L. Annable, A. Ross-Chouinard, M. Olivier and F. Fontaine, Piracetam in elderly psychiatric patients with mild diffuse cerebral impairment, Psychopharmacology, 81, 2, (100), (1983).
